Orphazyme A/S

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

GT Biopharma Inc

Workhorse Group

These former penny stocks have followed the path of AMC stock this month The post 3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021

Orphazyme A/S's (NASDAQ: ORPH) major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company's shares. What Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company's share capital.

Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally

ARK Genomic Revolution Multi-Sector ETF

Biogen

Principal Healthcare Innovators Index ETF

Clover Health Investments

First Trust NYSE Arca Biotechnology Index Fund

Global X Genomics & Biotechnology ETF

ALPS Medical Breakthroughs ETF

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

Top-Performing Biotech ETFs of Last Week

Novavax

Avenue Therapeutics

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID-19 Results: After a protracted delay, Gaithersburg, Maryland-based Novavax reported preliminary results showing its coronavirus candidate NVX-CoV2371 met the primary endpoint of the Phase 3 PREVENT trial in the U.S. and Mexico.

Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

The stock price of Orphazyme (NASDAQ: ORPH) increased by over 20% pre-market. These are the details.

ORPH Stock Price: Over 20% Increase Pre-Market Details

CytRx

Fortress Biotech

Mustang Bio

MEI Pharma

Matinas BioPharma Hlds

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Shares of a small Denmark biotechnology company surged as much as 1,387% in US trading hours Thursday as chatter about the stock jumped on Reddit's Wall Street Bets. Orphazyme, which is researching treatment for rare diseases, closed the day 302% higher in the US. In Denmark Friday it continued to rally as much as 88%, according to Bloomberg data.

A Danish biotech stock surged 1,387% during US trading hours for no apparent reason amid chatter that it's getting the meme-stock treatment

The stock price of Orphazyme A/S (NASDAQ: ORPH) fell by over 50% pre-market. These are the details.

ORPH Stock Price: Over 50% Decrease Pre-Market Explanation

Shares of Orphazyme A/S plunged 50.2% in active premarket trading Friday, after rocketing fourfold in the previous session, after the Denmark-based biopharmaceutical company said overnight that wasn't aware of any reason for the recent "extreme volatility." Trading volume was already up to 4.1 million shares before Friday's open, compared with the full-day average over the past 30 days of about 286,000 shares, according to FactSet On Thursday, the stock had soared as much 1,387% intraday before closing up 301.5% on volume of 7.9 million shares, and was halted a total of 22 times for volatility during the day.

Orphazyme stock losing half its value premarket, after rocketing fourfold the day before

Orphazyme A/SCompany announcement        No. 15/2021Company Registration No. 32266355

Orphazyme addresses recent trading activity

Orphazyme A/S (NASDAQ: ORPH) shares skyrocketed over 300% in the regular session on Thursday. What Happened: Shares of the Denmark-based biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%.

Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Today, Orphazyme stock is on the move and is trading with extremely heavy volume, as momentum traders drive up the value of this small cap. The post Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket appeared first on InvestorPlace.

Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket

The stock price of Orphazyme (NASDAQ: ORPH) increased by over 1,386% during intraday trading. This is why it happened.

ORPH Stock Price: Over 1,386% Increase Explanation

Shares of Orphazyme A/S blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m.

Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

Amesite Operating

Support.com

vTv Therapeutics

Wondering what penny stocks are? Here's your answer and 4 to watch The post What Are Penny Stocks?

What Are Penny Stocks? 4 to Buy [Or Sell] In 2021

Today, ORPH stock is on the move, on what appears to be no real catalysts as momentum traders pile into this small cap stock. The post ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?

ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?

NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that the ORARIALS-01 pivotal trial for arimoclomol in Amyotrophic Lateral Sclerosis (“ALS”) did not meet primary and secondary endpoints to show benefit in people living with the disease. According to Orphazyme, no import

CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Orphazyme A/SCompany announcement No. 14/2021Inside informationCompany Registration No. 32266355

Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Orphazyme A/SInvestor news        No. 05/2021Company Registration No. 32266355

Orphazyme to present at upcoming investor conferences

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (“IBM”) did not meet its primary and secondary endpoints. According to Orphazyme, the primary goal was to evaluate the treatment

CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis

Orphazyme A S (NASDAQ: ORPH) saw its stock plunge on Monday after failing to meet primary and secondary endpoints in a Phase 2/3 trial. The experimental drug, arimoclomol, was being tested in 150 inclusion body myositis patients against a placebo, a muscle-wasting disease.

Why Is Orphazyme (ORPH) Stock Trading Lower On Monday?

Orphazyme (NASDAQ:ORPH) is currently down 30.59% to a price of $8.75. The stock's current volume for the day is 327.17 thousand, which is approximately 5917.33% of its previous 30-day average volume of 5.53 thousand.

Why Orphazyme's Stock is Down During Today's Session

Copenhagen – March 29, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of neurodegenerative rare diseases, today announced its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (IBM), a progressively debilitating muscle-wasting disease, did not meet its primary and secondary endpoints. The primary goal was to evaluate the treatment effect on disease progression as measured by the inclusion body myositis functional rating scale (IBMFRS).

Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)

Orphazyme A/SCompany announcement                                                                                        No. 10/2021                                                                                                           Company Registration No. 32266355

News for Orphazyme A/S Stock (ORPH)